5:09 PM
 | 
Jan 23, 2012
 |  BC Extra  |  Company News

FDA extends PDUFA date for Alexza's Adasuve

FDA extended the PDUFA date by three months for an NDA from Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) for inhaled Adasuve Staccato loxapine to treat...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >